Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study. [electronic resource]
Producer: 20180209Description: 66480-66490 p. digitalISSN:- 1949-2553
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bone Neoplasms -- drug therapy
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Crown Ethers -- administration & dosage
- Diphosphonates -- administration & dosage
- Disease-Free Survival
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride -- administration & dosage
- Female
- Gefitinib
- Humans
- Imidazoles -- administration & dosage
- Kaplan-Meier Estimate
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation
- Pamidronate
- Protein Kinase Inhibitors -- administration & dosage
- Quinazolines -- administration & dosage
- Retrospective Studies
- Treatment Outcome
- Zoledronic Acid
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.